Among these causal protein candidates, 107 were previously reported to be associated with CVD or CVD‐related traits, including therapeutic drug targets that have been approved or with ongoing clinical trials, such as PCSK9 for myocardial infarction, stroke, and coronary revascularization, ANGPTL3 for reducing low‐density lipoprotein cholesterol, and ECE1 for congestive heart failure and hypertension (Table S2, Supporting Information). Here, ANGPTL3 is linked to myocardial infarction.